NCT03936465: Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitor BMS-986158 in Pediatric Cancer

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BET, BRD, MYC
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 21 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients with 1 amplification or translocation MYCN or MYC, or 2 translocation of BRD3 or BRD4 will be assigned to Cohort B; All others will be assigned to Cohort A

Up ↑